NeuroEndocrine Cancer Australia

Click on the "Follow" button below and you'll get the latest news from NeuroEndocrine Cancer Australia via email, mobile or you can read them on your personal news page on this site.

You can unsubscribe anytime you want easily.

You can also choose the topics or keywords that you're interested in, so you receive only what you want.

NeuroEndocrine Cancer Australia title: NeuroEndocrine Cancer Australia

Is this your feed? Claim it!

Publisher: Unclaimed!

Message frequency: 0.23 / day

Message History

Why Your Donation to NeuroEndocrine Cancer Australia Funds Research That Changes Lives1 week

We’re often asked by donors and supporters how they can contribute specifically to neuroendocrine cancer (NET) research. This article is an overview of what NeuroEndocrine Cancer Australia (NECA) is currently involved in, and how your donation directly supports that work. Where your research dollar goes NECA doesn’t just talk about supporting research, it is an […]

Read full story

NECA welcomes PBS listing of Selpercatinib for medullary thyroid cancer2 weeks

NeuroEndocrine Cancer Australia (NECA) welcomes the Pharmaceutical Benefits Scheme (PBS) listing of Selpercatinib (Retevmo) for eligible Australians living with advanced or metastatic medullary thyroid cancer (MTC) with RET mutation effective from 1 August 2026. Medullary thyroid cancer is a rare neuroendocrine cancer arising from the parafollicular (C) cells of the thyroid. App...

Read full story

July 20264 weeks

Read full story

NECA Attends Rare Conversations4 weeks

NECA recently joined the second Rare Conversations event, hosted by the Patient Voice Initiative and Alexion, to discuss PBS reform for rare disease treatments. It was a valuable opportunity to advocate on behalf of the NET community and connect with fellow rare disease organisations working towards greater access and equity. Invited to be on the […]

Read full story